Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

被引：61

作者：

Cortes, J. ^{[1
]}

Calvo, V. ^{[2
]}

Ramirez-Merino, N. ^{[3
]}

O'Shaughnessy, J. ^{[4
,5
]}

Brufsky, A. ^{[6
]}

Robert, N. ^{[7
]}

Vidal, M. ^{[1
]}

Munoz, E. ^{[1
]}

Perez, J. ^{[1
]}

Dawood, S. ^{[8
]}

Saura, C. ^{[1
]}

Di Cosimo, S. ^{[1
]}

Gonzalez-Martin, A. ^{[9
]}

Bellet, M. ^{[1
]}

Silva, O. E. ^{[10
]}

Miles, D. ^{[11
]}

Llombart, A. ^{[12
]}

Baselga, J. ^{[13
]}

机构：

[1] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain

[2] Hosp Ramon & Cajal, Dept Med Oncol, E-28034 Madrid, Spain

[3] Hosp Univ Guadalajara, Dept Med Oncol, Guadalajara, Spain

[4] Baylor Charles Sammons Canc Ctr, Dept Med Oncol, Dallas, TX USA

[5] US Oncol, Dallas, TX USA

[6] Univ Pittsburgh, Med Ctr, Dept Med Oncol, Pittsburgh, PA USA

[7] Virginia Canc Specialists, US Oncol, Dept Med Oncol, Fairfax, VA USA

[8] Dubai Hosp, Dubai Hlth Author, Dept Med Oncol, Dubai, U Arab Emirates

[9] MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain

[10] Univ Miami, Leonard M Miller Sch Med, Dept Med Oncol, Miami, FL USA

[11] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England

[12] Arnau de Vilanova Hosp, Dept Med Oncol, Lerida, Spain

[13] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 05期

关键词：

adverse events; bevacizumab; breast cancer; meta-analysis; safety; toxicity; GASTROINTESTINAL PERFORATION; GROWTH-FACTOR; PHASE-III; ANGIOGENESIS; TRIAL;

D O I：

10.1093/annonc/mdr432

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast cancer (MBC). A systematic review and meta-analysis was conducted to determine the risk of the most clinically relevant adverse outcomes associated with the use of bevacizumab in the treatment of breast cancer. We included phase III clinical trials that used bevacizumab alone or in combination with chemotherapy as for MBC or locally recurrent. Statistical analyses were conducted to calculate summary odds ratio (OR) of the eight most relevant adverse outcomes related with bevacizumab. Five clinical trials were included in the meta-analysis. Summary odds ratios obtained showed a statistically significant bevacizumab-associated increased risk in four of the adverse outcomes studied: proteinuria (OR = 27.68), hypertension (OR = 12.76), left ventricular dysfunction (LVD) (OR = 2.25), and hemorrhagic events (OR = 4.07). No statistically significant differences were found for gastrointestinal (GI) perforation, vascular events, fatal events, or febrile neutropenia. Bevacizumab did increase the risk of LVD and hemorrhagic events. The addition of bevacizumab to chemotherapy in patients with metastatic breast cancer was not associated with a significant increase in grade >= 3 arterial or venous thromboembolic events, GI perforation, or fatal events.

引用

页码：1130 / 1137

页数：8

共 27 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], COMM TERM CRIT ADV E

[4]

[Anonymous], AV BEV FDA DRUG LAB